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Abstract
Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography–computed
tomography (PET/CT) is useful in the preoperative diagnosis of gastrointestinal stromal
tumors (GISTs); however, the molecular characteristics of glucose metabolism of GIST are
unknown. We evaluated 18F-FDG uptake on preoperative PET/CT of 40 patients and ana-
lyzed the expression of glycolytic enzymes in resected GIST tissues by qRT-PCR, western
blotting, and immunohistochemistry. Results of receiver operating characteristic curve anal-
ysis showed that the maximum standardized uptake value (SUVmax) cut-off value of 4.99
had a sensitivity of 89.5%, specificity was 76.2%, and accuracy of 82.5% for identifying
tumors with a high risk of malignancy. We found that 18F-FDG uptake correlated positively
with tumor size, risk grade, and expression levels of glucose transporter 1 (GLUT1), hexoki-
nase 1 (HK1), and lactate dehydrogenase A (LDHA). Elevated HK and LDH activity was
found in high-risk tumors. Among the isoforms of GLUT and HK, GLUT1 and HK1 expres-
sion increased with higher tumor risk grade. In addition, overexpression of glycolytic
enzymes M2 isoform of pyruvate kinase (PKM2) and LDHA was observed in GISTs, espe-
cially in high-risk tumors. These results suggest that upregulation of GLUT1, HK1, PKM2,
and LDHAmay play an important role in GIST tumorigenesis and may be useful in the pre-
operative prediction of malignant potential.
Introduction
Gastrointestinal stromal tumors (GISTs), the most common non-epithelial neoplasms of the
gastrointestinal (GI) tract, are defined as “KIT or PDGFRAmutation-driven mesenchymal
tumors that can occur anywhere in the GI tract” [1]. Preoperative diagnosis of GISTs and
assessment of their malignant potential are difficult because most GISTs are located in the sub-
mucosa. Tumor grading is therefore based primarily on mitotic index and tumor diameter.
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The clinical usefulness of 18F-fluorodeoxyglucose (FDG) positron emission tomography–
computed tomography (PET/CT) has been demonstrated in tumor staging, treatment response
assessment, and prognosis prediction in various tumors [2–6]. This technique is also used in
tumor staging and evaluation of targeted therapy response in GISTs [7–12]. Many tumors
depend on aerobic glycolysis for rapid growth beyond that supported by the vasculature.
18F-FDG is an analogue of glucose that allows noninvasive evaluation of the tumor’s glucose
metabolism, which can predict treatment response and patient prognosis. 18F-FDG enters the
cell through glucose transporters (GLUT), is phosphorylated to 18F-FDG-6-PO4 by hexokinase
(HK), and is then “trapped” in the cell as it is not further metabolized, allowing PET/CT acqui-
sition 1 hour after 18F-FDG injection. Upregulation of GLUT and HK expression is associated
with increased glucose metabolism and 18F-FDG uptake in tumors. For example, previous
studies have shown that increased GLUT1 expression correlates with higher 18F-FDG uptake
in lung and breast carcinomas [13–15].
Although 18F-FDG PET/CT is useful for the preoperative diagnosis of GISTs, the detailed
molecular mechanisms underlying glucose metabolism in these tumors and specific character-
istics associated with tumor risk grade are not well understood. Tumor cells consume large
amounts of glucose and produce large amounts of lactate compared to normal cells, even in the
presence of oxygen. This metabolic switch from oxidative phosphorylation to increased glycol-
ysis (i.e., the Warburg effect) is a common characteristic of malignant tumors [16, 17] and reg-
ulated by transcription factors, such as hypoxia inducible factor-1α (HIF-1α), v-myc avian
myelocytomatosis viral oncogene homolog (c-Myc), and tumor suppressor p53 (p53) [18–20].
In gastric cancer, 18F-FDG accumulation represents tissue hypoxia, rather than GLUT expres-
sion [21]. However, analysis of the enzymes involved in glycolysis has not been performed in
GISTs, and it is unclear whether the Warburg effect occurs in GISTs. Qualitative and quantita-
tive analysis of glycolytic enzyme expression and their relationship with GIST tumor risk grade
may clarify whether the Warburg effect occurs in GISTs. In this study, we aimed to identify 1)
the relationship between maximum standardized uptake value (SUVmax) on preoperative
18F-FDG PET/CT with GLUT and HK expression in GISTs, 2) the specific isoforms of GLUT
and HK that are upregulated according to GIST tumor risk grade, and 3) alterations in the
expression of various glycolytic enzymes according to tumor risk grade. By performing this
study, we expect to identify the molecular biomarkers predictive of malignant GISTs that can
be used in preoperative biopsy or cytology specimens and the molecular mechanisms of GIST
detection by 18F-FDG PET/CT.
Materials and Methods
Patient Selection
Our patient selection criteria specified the inclusion of patients diagnosed with GIST who
underwent surgery after preoperative 18F-FDG PET/CT, and a total of 40 GIST patients were
included in our study. The cases were identified prospectively and consecutively between 2003
and 2013 at Severance Hospital, Yonsei University College of Medicine and from the Liver
Cancer Specimen Bank, National Research Resource Bank Program of the Korea Science and
Engineering Foundation of the Ministry of Science and Technology. Written informed consent
for use of GIST tissues was obtained from all patients, and use of these tissues for research pur-
poses was approved by the Institutional Review Board of Yonsei University of College of Medi-
cine (IRB approval No.4-2015-0227). Risk of malignancy was categorized according to the
system described by Fletcher et al [22].
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Mutational analysis
DNA extraction was performed by using the QIAamp DNA FFPE Tissue Kit (Qiagen, GmbH,
Hilden, Germany) according to the manufacturer’s instructions. Primer sequences used to
amplify v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) exons are
shown in S1 Table. PCR was carried out using a Veriti thermal cycler (Life Technologies, USA)
with the following amplification conditions: 35 cycles of denaturation at 94°C for 30 s, anneal-
ing at 60°C for 30 s, and extension at 72°C for 1 min. The amplified products were purified
using Agencourt AMPure XP (Beckman Coulter Genomics, Danvers, MA), and direct
sequencing was performed using the BigDye Terminator Ready Reaction Cycle Sequencing kit
and an ABI Prism 3130 genetic analyzer (Life Technologies).
PET/CT protocol and quantification
All patients underwent routine 18F-FDG PET/CT scans with either the DSTe PET/CT scanner
(GE Healthcare, Milwaukee, WI) or the Biograph TruePoint 40 PET/CT scanner (Siemens
Medical Systems, CTI, Knoxv/ille, TN). Before 18F-FDG injections, all patients fasted for at
least 6 hours, and peripheral blood glucose levels were confirmed to be140 mg/dL. The
18F-FDG dose of approximately 5.5 MBq/kg body weight was administered intravenously 1
hour before image acquisition. After the initial low-dose CT (DSTe: 30mA, 130 kVp, Biograph
TruePoint: 36 mA, 120 kVp), standard PET imaging was performed from neck to the proximal
thighs (acquisition time, 3 min/bed) in three-dimensional mode. Images were then recon-
structed using ordered-subset expectation maximization (2 iterations, 20 subsets). Written
informed consent was obtained from all patients undergoing 18F-FDG PET/CT scans.
Images were reviewed by an experienced nuclear medicine specialist on a GE AW 4.0 work-
station. On PET scans, a volume of interest (VOI) was drawn on the primary lesion; SUVmax
of the GIST was recorded.
Immunohistochemistry
Formalin-fixed and paraffin-embedded GIST tissue specimens were cut into 4-μm thick sec-
tions, and immunohistochemistry (IHC) analysis was performed using the Ventana Discovery
XT autoimmunostainer (Ventana, Tucson, AZ) with antibodies against GLUT1 (1:100; Milli-
pore, Temecula, CA), GLUT3 (1:100; Proteintech, Chicago, IL), GLUT4 (1:200; Abcam, Cam-
bridge, MA), HK1 (1:800; Cell Signaling Technology, Beverly, MA), HK2 (1:500; Cell Signaling
Technology), PKM2 (1:500; Cell Signaling Technology), LDHA (1:100; Cell Signaling Technol-
ogy), HIF-1α (1:100; Novus Biologicals, Littleton, CO), p53 (1:100; Dako, Glostrup, Denmark),
and c-Myc (1:100; Santa Cruz Biotechnology, Santa Cruz, CA). IHC results were scored based
on staining intensity as follows: 0, no staining; 1, weak staining (faint protein expression in
tumor cells or definite expression in<30% of tumor cells); or 2, strong staining (definite pro-
tein expression in>30% of tumor cells).
Western blotting
Whole lysates from GIST tissues were prepared using passive lysis buffer (Promega, Madison,
WI) with a protease inhibitor cocktail (Roche, Mannheim, Germany). Total protein lysates
(5 μg) were loaded into each lane, size-fractionated by SDS-PAGE and transferred to a nitrocel-
lulose membrane that was blocked with Tris-buffered saline-Tween 20 containing 5% skim
milk. Primary antibodies against GLUT1 (1:500; Millipore), HK1 (1:1000; Cell Signaling Tech-
nology), PKM2 (1:1000; Cell Signaling Technology), LDHA (1:1000; Cell Signaling Technol-
ogy), β-actin (1:2000; Cell Signaling Technology), and glyceraldehyde 3-phosphate
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dehydrogenase (GAPDH, 1:100,000; Trevigen, Gaitherburg, MD) were incubated with the
membrane for overnight at 4°C. After washing, membranes were incubated with goat anti-rab-
bit or mouse IgG-HRP conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), washed, and then developed using western blotting luminol reagent (Santa Cruz Biotech-
nology). Protein band intensity was analyzed by using a LAS-4000 Mini camera (Fujifilm,
Tokyo, Japan).
Quantitative reverse transcription-polymerase chain reaction
Primer sequences are listed in S2 Table. Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) analysis was carried out in a final reaction volume of 20 μl with Premix Ex
Taq II (Takara Bio, Otsu, Japan) according to the manufacturer’s protocol. All reactions were
run in triplicate on the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City,
CA).
Hexokinase and lactate dehydrogenase activity assay
Hexokinase (HK) and lactate dehydrogenase (LDH) activities in GIST tissues were determined
using a colorimetric (450 nm) kit (Sigma-Aldrich, St Louis, MO) according to the manufactur-
er’s recommended protocol. Each sample was diluted as necessary to fall in the linear range of
the standard curve and assayed in duplicate. Briefly, 10 μl samples were mixed with assay buffer
in HK activity assay and 5 μl samples were mixed with assay buffer in LDH activity assay.
Absorbance was measured at room temperature every 5 minutes (HK activity) and at 37°C
every 2–3 minutes (LDH activity). Both enzyme activities were assessed using the following
equation: B × sample dilution factor/(Tfinal—Tinitial) × V; where B is the amount of NADH gen-
erated between Tinitial and Tfinal, and (Tfinal—Tinitial) indicates the reaction time. V is the sample
volume (mL) added to the reaction well. All data were expressed as milliunit per mg of total
protein. One unit of HK and LDH is the amount of enzyme that generate 1 μmole of NADH
per minute.
Statistical analysis
Relationships between tumor risk grade and other parameters were evaluated using either chi-
square test or one-way analysis of variance. Correlation analysis was performed with Pearson’s
or Spearman’s correlation test. Student’s t-test was used to compare two groups of continuous
variables. The area under the receiver operating characteristic (ROC) curve was used to deter-
mine the SUV cut-off level able to predict tumor risk grade with the highest sensitivity. Data
are expressed as mean ± standard deviation (SD); P< .05 was considered significant. Statistical
analysis was performed using SPSS for Windows (version 21.0; SPSS Inc., USA).
Results
Clinicopathologic characteristics and 18F-FDG uptake of 40 GISTs
Of the 40 patients included in the study, 22 were women and 18 were men (S3 Table), and
mean patient age was 59 years (range 20–83). Of the 40 GIST lesions, 18 were located in the
stomach, 22 were located in the small or large intestine. Five lesions were not well visualized on
PET (SUVmax<2.5), 12 showed moderate FDG uptake (2.5<SUVmax<5.0), and 23 showed
intense FDG uptake (SUVmax5.0). High-risk tumors were more common in men (Table 1).
Histologic features of representative cases are shown in Fig 1A.
FDG uptake did not differ significantly between gastric GISTs and non-gastric GISTs (data
not shown); however, SUVmax strongly correlated with tumor size (r = 0.716, P< .001). In
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addition, SUVmax was lower in tumors with low mitotic count (10/50 high-power fields
[HPF]) than in tumors with high mitotic count (>10/50 HPF) (5.4±3.7 vs. 10.7±5.4, respec-
tively; P< .001) (S1 Fig).
Table 1. Relationships between GIST risk grade and 18F-FDG uptake and demographic and clinicopathologic factors.
Variable category Tumor risk grade
Low (n = 13) Intermediate(n = 8) High (n = 19) P value
Age, years 57.5±13.3 61.5±19.4 58.4±12.5 0.814
Gender, n
Male 5 1 12 0.046*
Female 8 7 7
Tumor size, cm 3.2±1.0 5.9±2.1 9.6±4.0 < .001*
Mitotic count, /50 HPF 2.1±1.3 4.9±3.5 27.5±35.2 0.013*
SUVmax 4.3±3.2 5.4±2.7 10.9±5.2 < .001*
Results are expressed as mean±SD unless otherwise indicated.
*P value was calculated either by chi-square test or one-way analysis of variance
doi:10.1371/journal.pone.0141413.t001
Fig 1. Histologic features of GISTs and Representative cases showing 18F-FDG uptake intensity
according to tumor risk grade. (A) Low-risk GIST showing proliferation of bland-looking spindle cells with
infrequent mitoses (1/50 HPFs) (left panel). Intermediate-risk GIST showing mild nuclear pleomorphism
(dashed line) with occasional mitosis (10/50 HPFs; black arrows) (middle panel). High-risk GIST showing
proliferation of spindle cells with hyperchromatic nuclei (white arrows), moderate pleomorphism, and frequent
mitoses (13/50 HPFs) (right panel). Scale bar, 100μm; ×200. (B) Low-risk GIST: 58-year-old man with mild
18F-FDG uptake (SUVmax = 2.2) in the proximal jejunum (left panel). Intermediate-risk GIST: 73-year-old
woman with moderate 18F-FDG uptake (SUVmax = 4.9) (middle panel). High-risk GIST: 65-year-old woman
with intense 18F-FDG uptake (SUVmax = 19.2) (right panel).
doi:10.1371/journal.pone.0141413.g001
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Correlation between 18F-FDG uptake and tumor risk grade
Tumor risk grade [22] correlated significantly with 18F-FDG uptake (P< .001) (Table 1 and
Fig 1B). SUVmax was lower for low-risk (4.3±3.2) and intermediate-risk tumors (5.4±2.7) than
for high-risk tumors (10.9±5.2; P< .001).
To evaluate the usefulness of 18F-FDG PET/CT in predicting the malignant potential of
GISTs, we compared high-risk tumors with intermediate- and low-risk tumors. ROC curve
analysis showed that a SUVmax cut-off of 4.99 was the most sensitive for predicting malig-
nancy, and area under curve was 0.875 (P< .001). Using this SUVmax cut-off value to differ-
entiate high-risk tumors from low- and intermediate-risk tumors, sensitivity was 89.5% (16/
18), specificity was 76.2% (17/22), and accuracy was 82.5% (32/40).
Overexpression of GLUT1 and HK1 in GISTs according to tumor risk
grade
Because isoforms of GLUT and HK are overexpressed in tumors and associated with 18F-FDG
uptake, we evaluated the expression of four isoforms of GLUT (GLUT 1, 2, 3, and 4) and two
isoforms of HK (HK1 and HK2) in the 40 GISTs. First, we analyzed total HK activity. We
found that HK activity was significantly upregulated in high-risk GISTs, compared to low-risk
and intermediate-risk GISTs (P< .05) (Fig 2A). Results of qRT-PCR analysis showed gradual
increases in GLUT1 and HK1 expression with higher tumor risk grade (Fig 3A). In contrast,
Fig 2. HK and LDH activity in GISTs. (A) (B). Elevated HK and LDH activities are found in high-grade
GISTs. Results are expressed as mean±SD of three independent experiments. *P < .05; **P < .01 based on
the Student’s t-test.
doi:10.1371/journal.pone.0141413.g002
Molecular Mechanisms of ¹⁸F-FDG Uptake in GISTs
PLOS ONE | DOI:10.1371/journal.pone.0141413 October 28, 2015 6 / 13
expression of GLUT 2, 3, 4, andHK2 was not correlated with tumor risk grade at both the
mRNA and protein level (S2A and S2B Fig). Expression of GLUT1 was significantly increased
in high-risk GISTs (1.3±1.32) compared to low-risk GISTs (0.27±0.32; P< .01). Similarly, HK1
expression was increased in intermediate-risk (1.65±0.48) and high-risk GISTs (1.58±1.10)
compared to low-risk GISTs (0.94±0.68; P< .05).
We next analyzed GLUT1 and HK1 protein expression by IHC and western blot analysis.
GLUT1 and HK1 protein were detected in most GISTs; however, GLUT1 was not detected in
four GISTs, and HK1 was not detected in five GISTs (Table 2). Most of the tumors lacking
expression of these two proteins were low-risk GISTs (Table 2 and Fig 4A). Results of IHC
staining showed that SUVmax correlated with both GLUT1 expression (rs = 0.465, P = 0.002)
and HK1 expression (rs = 0.446, P = 0.004) (Fig 4B). These findings suggest that GLUT1 and
HK1 expression are related to PET signals. Results of western blotting analysis showed expres-
sion patterns of GLUT1 and HK1 that were similar to qRT-PCR and IHC results (Fig 4C).
Enhanced expression of PKM2 and LDHA in high-risk GISTs
In order to elucidate the presence of the Warburg effect in GISTs, we evaluated mRNA and
protein expression levels for PKM2 and LDHA. Results of qRT-PCR showed a gradual increase
in PKM2 and LDHA expression with higher tumor risk grade (Fig 3B). PKM2 expression was
significantly higher in high-risk GISTs (3.39±3.51) than in low-risk (0.69±0.67) and intermedi-
ate-risk GISTs (0.85±0.36; P< .05). Similarly, LDHA expression was significantly higher in
high-risk GISTs (1.37±1.09) than in low-risk (0.49±0.63) and intermediate-risk GISTs (0.89
±0.92; P< .05).
Next, we evaluated protein levels of PKM2 and LDHA in the 40 GISTs by IHC and western
blotting analysis. These two glycolytic enzymes were detected in most GISTs; however, PKM2
was not expressed in eight GISTs (Table 2). Most of the tumors lacking protein expression of
these enzymes were low-risk GISTs. Protein levels of PKM2 and LDHA were increased in
Fig 3. GLUT1,HK1, PKM2, and LDHA expression according to GIST risk grade, as assessed by
quantitative RT-PCR. (A) (B).GLUT1, HK1, PKM2, and LDHAmRNA levels increased with higher tumor risk
grade. L = low risk; I = intermediate risk; H = high risk. *P < .05; **P < .01 based on the Student’s t-test.
doi:10.1371/journal.pone.0141413.g003
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intermediate- and high-risk GISTs (Table 2 and Fig 5A). We also found a positive correlation
between SUVmax and LDHA protein expression. SUVmax was significantly higher in tumors
with strong LDHA expression than in tumors with weak LDHA expression (rs = 0.466,
P = 0.002) (Fig 5B). Results of western blotting analysis showed that PKM2 and LDHA expres-
sion patterns were similar to IHC results (Fig 5C). Additionally, we measured LDH activity in
our GIST tissues to evaluate metabolism status. LDH activity was significantly upregulated in
high-risk GISTs, compared to low-risk and intermediate-risk GISTs (P< .01) (Fig 2B). These
findings suggest that upregulation of LDHA is involved in the malignant potential and PET sig-
nal of GISTs.
We further evaluated the relationship between the glycolysis-modulating transcription factors
and glycolytic markers that we had selected (GLUT1, HK1, PKM2, and LDHA). First, we ana-
lyzed HIF-1α, c-Myc, and p53 expression using qRT-PCR and IHC.We found that mRNA
expression levels ofHIF-1α were higher in high-risk GISTs (1.38±0.80) than in low-risk (0.66
±0.22) and intermediate-risk GISTs (1.02±0.63; P< .05). The expression levels of c-Myc and p53,
however, did not differ according to GIST risk grade (S3A Fig). IHC staining revealed positive
HIF-1α expression in 24 lesions (24/40; 60.0%); 14 of these 24 lesions (58.3%) were high-risk
GISTs. All of the GIST specimens were positive for c-Myc, an oncogenic transcription factor. In
contrast, expression of p53, a tumor suppressor, was negative in 38 lesions (95.0%) (S3B Fig).
Analyzing the correlations between each of the glycolytic markers and these transcription factors,
we found that onlyHIF-1α expression showed moderated correlation with GLUT1 (r = 0.390,
P< .05),HK1 (r = 0.406, P< .05), and LDHA (r = 0.336, P< .05) at the mRNA level (S4 Fig).
Discussion
In this study, we evaluated clinicopathologic factors contributing to 18F-FDG uptake in the
GISTs of 40 consecutive patients. Positive correlations were found between 18F-FDG uptake
Table 2. Relationships between GLUT1, HK1, PKM2, and LDHA immunohistochemical expression and GIST tumor risk grade.
Category Tumor risk grade
Low (n = 13) Intermediate (n = 8) High (n = 19) P value
GLUT1, n (%)
Negative 3 (23.1) 0 (0.0) 1 (5.3) 0.024*
Weak 10 (76.9) 7 (87.5) 10 (52.6)
Strong 0 (0.0) 1 (12.5) 8 (42.1)
HK1, n (%)
Negative 4 (30.8) 0 (0.0) 1 (5.3) 0.036*
Weak 9 (69.2) 6 (75.0) 11 (57.9)
Strong 0 (0.0) 2 (25.0) 7 (36.8)
PKM2, n (%)
Negative 6 (46.2) 1 (12.5) 1 (5.3) 0.02*
Weak 7 (53.8) 6 (75.0) 12 (63.2)
Strong 0 (0.0) 1 (12.5) 6 (31.6)
LDHA, n (%)
Negative 0 (0.0) 0 (0.0) 0 (0.0) 0.016*
Weak 10 (76.9) 3 (37.5) 5 (26.3)
Strong 3 (23.1) 5 (62.5) 14 (73.7)
*P value was calculated either by chi-square test or Fisher’s exact test.
doi:10.1371/journal.pone.0141413.t002
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and several clinicopathologic features and metabolic factors. SUVmax correlated with tumor
size; expression of GLUT1, HK1, and LDHA; and NIH risk group. 18F-FDG uptake was also
significantly higher in GISTs with mitotic count>10/50 HPF compared to GISTs with lower
mitotic count. The optimal SUVmax cut-off value for identifying tumors with a high risk of
malignancy (NIH risk classification) was 4.99 (sensitivity, 89.5%; specificity, 76.2%). These
findings suggest that PET/CT may be useful for preoperative assessment of malignant
potential.
We demonstrated significant overexpression of GLUT1 and HK1 protein in high-risk
GISTs by IHC and western blot analysis. We also demonstrated that HK activity in upregulated
in high-risk GISTs. GLUT and HK are important for glucose uptake, and the GLUT family of
transporters has been implicated in 18F-FDG uptake, with GLUT1 and GLUT3 in particular
playing important roles in 18F-FDG accumulation [13, 23]. The role of HK in 18F-FDG uptake
has been studied in various tumors [15, 24, 25]. In our study, the isoforms GLUT1 and HK1
were specifically overexpressed in high-risk GISTs, however, the expression levels of GLUT2, 3,
4, and HK2 showed no relationship with GIST risk grade. Overexpression of GLUT1 in the cell
membrane had been reported in many tumors, and overexpression of GLUT2 and GLUT3 has
been reported in hepatocellular carcinoma and malignant lymphoma, respectively [26, 27].
Although GLUT1, as well as GLUT3 and GLUT4, expression was found in one GIST cell line
Fig 4. SUVmax correlated with GLUT1 and HK1 expression. (A) Immunohistochemical analysis of GLUT1 and HK1 expression in representative tumor
tissues (×200). (B) Correlation between 18F-FDG uptake and GLUT1 and HK1 expression (rs = Spearman’s correlation coefficient). (C) Western blotting and
densitometric analysis of GLUT1 and HK1 expression in representative tissues. The densitometric data are normalized to GAPDH and shown as arbitrary
units. L = low risk; I = intermediate risk; H = high risk. *P < .05; **P < .01 based on the Student’s t-test.
doi:10.1371/journal.pone.0141413.g004
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(GIST-T1) [28], only the expression of GLUT1 was related to GIST risk grade. The paired over-
expression of GLUT1 and HK1 in GISTs, and the correlation between increased overexpres-
sion of these two proteins and tumor risk grade provide evidence for increased glucose uptake
and abnormal glucose metabolism in GISTs, which may be useful in preoperative diagnosis
and the development of novel therapeutic targets.
In this study, we demonstrated that theWarburg effect exists in GISTs and observed a correla-
tion between 18F-FDG uptake and tumor risk grade. Most GISTs evaluated in this study showed
significant overexpression of the glycolytic enzymes PKM2 and LDHA, with the degree of over-
expression increasing with higher tumor risk grade. We tried to identify which transcription fac-
tors induce glycolytic markers in GISTs and found moderate correlation between HIF-1α
expression and GLUT1, HK1, and LDHA expression. This metabolic switch from oxidative
phosphorylation to increased glycolysis is one of the principle biochemical characteristics of
malignant cells [16]. In addition, PKM2 possesses protein tyrosine kinase activity and plays a
role in modulating gene expression, thereby contributing to tumorigenesis [29]. For example,
enhanced PKM2 expression correlates with aggressive tumor behavior (in vivo tumor growth,
tumor cell proliferation, migration) in colon cancer [30]. LDHA expression is also elevated in
many types of cancers and is linked to tumor growth, maintenance, and invasion [31–34]. There-
fore, LDHA inhibition may restrict the energy supply in cancer cells, thereby decreasing their
Fig 5. SUVmax correlated with LDHA expression. (A) Immunohistochemical analysis of PKM2 and LDHA expression in representative tumor tissues. (B)
Correlation between 18F-FDG uptake and PKM2 and LDHA protein expression (rs = Spearman’s correlation coefficient). (C) Western blotting and
densitometric analysis of PKM2 and LDHA expression in representative tissues. The densitometric data are normalized to β-actin and shown as arbitrary
units. *P < .05; **P < .01 based on the Student’s t-test.
doi:10.1371/journal.pone.0141413.g005
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tumorigenicity [24, 35]. This enzyme may also be useful as a diagnostic marker or predictive bio-
marker for many types of cancer, as well as a therapeutic target for new anti-cancer treatments.
In addition, the correlation between 18F-FDG accumulation and LDHA expression and the possi-
ble modulation of 18F-FDG uptake through LDHA-AKT-GLUT1 signaling has been reported in
lung adenocarcinoma [24]. Based on these reports, our findings showing overexpression of
PKM2 and LDHA and the correlation between degree of expression and tumor risk grade in
GISTs indicate that overexpression of PKM2 and LDHAmay play important roles in GIST
tumorigenesis and suggest their usefulness as potential therapeutic targets.
In conclusion, we evaluated the usefulness of preoperative 18F-FDG PET/CT for the predic-
tion of malignant potential in GISTs and the relationship between tumor risk grade and the
expression of proteins involved in glucose metabolism. Our results showed that 18F-FDG
uptake correlates with tumor size, tumor risk grade, and expression levels of GLUT1, HK1, and
LDHA. The increased expression of GLUT1, HK1, PKM2, and LDHA with higher tumor risk
grades indicates important roles for these proteins in GIST tumorigenesis and suggests their
usefulness in the preoperative prediction of malignant potential.
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